The Cellular, Molecular and Morphological Core provides a wide range of essential services for the Program Project. We have assembled, as part of our program, a team of supporting cellular and molecular biologists to assist us in the investigation of the molecular aspects of solid tumor physiology. The use of the services of Core B for 81 of 90 original articles published since 2006 provides the strongest evidence of the benefit of the Core to the Program. The molecular biology component will provide the expertise, apparatus, assay protocols, and essential reagents for the characterization of gene expression and regulation. These routine services include isolation and purification of DNA, RNA and proteins, in situ hybridization. Southern, Northern and Western blot analysis, the generation of DNA constructs, promoter analysis, the modification of gene expression in tumor and host stromal cell lines, and genotyping of transgenic animals. The cell culture component will provide the expertise and services, including the maintenance of parental and transfected cell lines, quality control, and maintenance of supplies. The morphology component will provide equipment, supplies and protocols as well as expertise and services for the analysis of tissues and cells, including fixation, embedding and sections preparation, as well as performing routine staining and immunohistochemical procedures. The flow cytometry component will provide equipment, supplies, protocol and services for characterization of specific cell populations. In addition to providing these services, the Core personnel will interact with Project Investigators to provide strategic consultation in the design of experimental procedures, to introduce innovative approaches using state-of-the-art techniques, and to assist in the completion of experiments and interpretation of data for molecular, cell and morphology studies. Finally, the Core personnel will assure reagent and antibody quality, manage biological information, acquire and store research materials, and maintain logs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
4P01CA080124-15
Application #
9057979
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
15
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
Khandekar, Melin J; Jain, Rakesh (2018) Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Transl Cancer Res 7:S16-S20
Stylianopoulos, Triantafyllos; Munn, Lance L; Jain, Rakesh K (2018) Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Trends Cancer 4:258-259
Grassberger, Clemens; Hong, Theodore S; Hato, Tai et al. (2018) Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys 101:1222-1225
Zhang, Na; Chen, Jie; Ferraro, Gino B et al. (2018) Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol 299:326-333
Aoki, Shuichi; Cobbold, Mark; Zhu, Andrew X et al. (2018) Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Hepatology 67:826-828
Li, Wende; Liu, Yujiao; Yang, Weining et al. (2018) MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma. J Neurooncol 136:63-71
Griveau, Amelie; Seano, Giorgio; Shelton, Samuel J et al. (2018) A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell 33:874-889.e7
Stylianopoulos, Triantafyllos; Munn, Lance L; Jain, Rakesh K (2018) Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside. Trends Cancer 4:292-319
Incio, Joao; Ligibel, Jennifer A; McManus, Daniel T et al. (2018) Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med 10:
Sung, Yun-Chieh; Liu, Ya-Chi; Chao, Po-Han et al. (2018) Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics 8:894-905

Showing the most recent 10 out of 320 publications